Biognosys will use its mass spectrometry technology to profile the proteome and phosphoproteome of clinical samples in Indivumed's oncology database.
Clonal hematopoiesis variants appear to outnumber tumor mutations in the plasma of most cancer patients, the investigators found in their study.
The test, which will be developed using the companies' respective technologies, will be marketed by Biolidics following clinical validation.
PWNHealth will enable Stratify to offer its Prompt Personal Genetic Score prostate cancer genetic risk test directly to consumers with medical oversight.
Researchers used single-cell sequencing to uncover developing brain cell populations from mice and humans with transcriptome features resembling those in pediatric brain tumors.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
A large genome-wide association in breast cancer cases and controls from Japan led to common variants linked to disease risk at two new and nine known risk loci.
Functional enhancers can accompany oncogenes on the circularized extrachromosomal amplicons found in glioma and other tumors, enhancing cancer growth.
Doctors can now order the test to identify breast cancer patients with BRCA1/2 mutations who may be eligible for surgery or targeted therapy.
The flow cytometry-based assays were developed by Menlo Park, California-based IncellDx to run on Beckman Coulter instrumentation.
Findings of a new study point to the need for technological solutions and education to improve local healthcare providers' ability to discuss genetic information with patients.
The company's revenues were generated entirely by its discovery services operations, which includes contract research for cancer drug development.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
While higher recurrence scores have been associated with increased mortality in women, the pattern of the association differed among male patients.
The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.
Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.
The firm also recently released the results of collaborations with Admera Health and RareCyte that used its multiplex PCR-based target enrichment technology.
Researchers found that about 12 percent to 15 percent of breast cancer patients carry multiple mutations in the gene, 95 percent of which are double mutations.
The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.
The partners plan to employ Personalis' ImmunoID NeXT platform to investigate biomarkers of response and mechanisms of resistance to cancer therapies.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.